KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Non-Current Assets (2018 - 2025)

Historic Non-Current Assets for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $88.8 million.

  • Aurinia Pharmaceuticals' Non-Current Assets fell 1846.71% to $88.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $385.5 million, marking a year-over-year decrease of 1699.21%. This contributed to the annual value of $104.0 million for FY2024, which is 1558.71% down from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Non-Current Assets is $88.8 million, which was down 1846.71% from $93.6 million recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Non-Current Assets peaked at $133.0 million during Q2 2023, and registered a low of $28.1 million during Q1 2023.
  • In the last 5 years, Aurinia Pharmaceuticals' Non-Current Assets had a median value of $88.8 million in 2025 and averaged $73.5 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Non-Current Assets plummeted by 3844.14% in 2021, and later soared by 35930.93% in 2023.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Non-Current Assets stood at $30.0 million in 2021, then dropped by 5.73% to $28.3 million in 2022, then soared by 335.23% to $123.3 million in 2023, then decreased by 15.59% to $104.0 million in 2024, then dropped by 14.66% to $88.8 million in 2025.
  • Its last three reported values are $88.8 million in Q3 2025, $93.6 million for Q2 2025, and $99.1 million during Q1 2025.